6/23/2024

Moxifloxacin Tablets

Products Affected - Description

- Moxifloxacin hydrochloride oral tablet, Major, 400 mg, unit-dose blister pack, 30 count, NDC 00904-7407-04
- Moxifloxacin hydrochloride oral tablet, Major, 400 mg, unit-dose blister pack, 50 count, NDC 00904-7407-06
- Moxifloxacin hydrochloride oral tablet, Rising Pharmaceuticals, 400 mg, bottle, 30 count, NDC 57237-0156-30

Reason for the Shortage

- Major did not provide a reason for the shortage. Major has updated the NDC numbers recently.
- Rising did not provide a reason for the shortage.
- Teva has moxifloxacin tablets available.
- Aurobindo refuses to provide availability information.

Available Products

- Moxifloxacin hydrochloride oral tablet, Teva, 400 mg, bottle, 30 count, NDC 00093-7387-56

Estimated Resupply Dates

- Major has moxifloxacin 400 mg tablets in unit-dose packaging on back order and the company estimates a release date in late-June 2024.
- Rising has moxifloxacin 400 mg tablets in 30 count bottles on back order and the company cannot estimate a release date.

Updated

Updated June 23, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created December 6, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.